Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2014. The report details a specific share repurchase transaction executed on February 11, 2014, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 95,756 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,634.50 pence per share; lowest price paid was 1,614.50 pence per share.
- Treasury Holdings (Settled): 487,970,663 shares, representing 9.13% of total issued share capital.
- Treasury Holdings (Including Unsettled): 488,423,669 shares, representing 10.06% of total voting rights.
- Shares in Issue (Excluding Treasury): 4,856,776,484 shares.
Material Changes
The filing reports an incremental increase in the Company's treasury share holdings following the purchase of 95,756 shares. No other material changes to financial position or operations are disclosed in this specific report.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a routine disclosure of a share repurchase transaction compliant with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (487,970,663 settled) against the latest quarterly or annual reports.
- Confirm the percentage of total voting rights held in Treasury (10.06% including unsettled shares) for disclosure threshold calculations.
- Check the total issued share capital excluding treasury shares (4,856,776,484) for accurate EPS and ownership percentage calculations.